Skip to search formSkip to main contentSkip to account menu

AS1404

National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2007
2007
5115 Background: DMXAA (AS1404) is a small-molecule agent that disrupts tumor vasculature. Combination of DMXAA with taxanes… 
2007
2007
4642 The anti-VEGF monoclonal antibody, bevacizumab, has been approved for use alongside chemotherapy in colorectal, non-small… 
2007
2007
BACKGROUND DMXAA (5,6-dimethylxanthenone-4-acetic acid; AS1404), a vascular disrupting agent currently in clinical trials… 
2007
2007
  • N. Moran
  • Nature Biotechnology
  • 2007
  • Corpus ID: 644609
Pharma's pipeline problems, coupled with the trend toward acquisition, are giving biotechs more leverage in licensing discussions… 
2007
2007
Purpose5,6-Dimethylxanthenone-4-acetic acid (DMXAA) (AS1404), a small-molecule vascular disrupting agent currently in clinical… 
2006
2006
Purpose 5,6-Dimethylxanthenone-4-acetic acid (DMXAA) (AS1404) is a novel antitumour agent that selectively disrupts tumour… 
2006
2006
SummaryAims: DMXAA (AS1404), a small-molecule vascular disrupting agent that has now completed Phase II clinical trial, induces… 
2006
2006
  • H. Gabra
  • Journal of clinical oncology : official journal…
  • 2006
  • Corpus ID: 23536090
5032 Background: DMXAA (AS1404) is a small-molecule vascular disrupting agent, which in animal models shows additive or supra… 
2006
2006
  • M. McKeage
  • Journal of clinical oncology : official journal…
  • 2006
  • Corpus ID: 22849845
7102 Background: DMXAA (AS1404) is a small-molecule vascular disrupting agent, which in animal models shows additive or supra… 
2005
2005
The selective targeting of established tumor vasculature represents an attractive new anticancer drug strategy, distinct from…